Abstract
Alzheimer’s disease is a unique neurodegenerative condition in humans that is characterized by amyloid beta accumulation in the brain parenchyma. Withania somnifera, commonly known as Ashwagandha, is a plant that has been used for centuries in Indian Ayurvedic medicine to treat various health conditions. The active compound in Ashwagandha has shown to be beneficial in treating several neurodegenerative diseases, including Alzheimer's disease (AD). This study used a Drosophila melanogaster AD model to investigate the effect of Ashwagandha in reducing amyloid beta toxicity and promoting longevity. The findings showed that 20 mg/mL of Ashwagandha root powder effectively rescued the "rough eye phenotype" in AD Drosophila and increased longevity in both AD model and wild-type Drosophila. Overall, the results suggest that Ashwagandha may have potent therapeutic potential for treating AD and maintaining cellular well-being.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asia Pacific Journal of Molecular Biology and Biotechnology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
